Spinal cord injury (SCI) is an important cause of traumatic paralysis and is mainly due to motor vehicle accidents. However, there is no definite treatment for spinal cord damage.

To assess the outcome of rat embryonic stem cells (rESC) and autologous bone marrow-derived neurocytes (ABMDN) treatment in iatrogenic SCI created in rats, and to compare the efficacy of the two different cell types.

The study comprised 45 male Wistar rats weighing between 250 and 300 g, which were divided into three groups, the control, rESC and ABMDN groups. The anesthetized animals underwent exposure of the thoracic 8^th to lumbar 1^st vertebrae. A T10-thoracic 12^th vertebrae laminectomy was performed to expose the spinal cord. A drop-weight injury using a 10 g weight from a height of 25 cm onto the exposed spinal cord was conducted. The wound was closed in layers. The urinary bladder was manually evacuated twice daily and after each evacuation Ringer lactate 5 mL/100 g was administered, twice daily after each bladder evacuation for the first 7 postoperative days. On the 10^th day, the rats underwent nerve conduction studies and behavioral assessment [Basso, Beattie, Brenham (BBB)] to confirm paraplegia. Rat embryonic stem cells, ABMDN and saline were injected on the 10^th day. The animals were euthanized after 8 wk and the spinal cord was isolated, removed and placed in 2% formalin for histopathological analysis to assess the healing of neural tissues at the axonal level.

All the animals tolerated the procedure well. The BBB scale scoring showed that at the end of the first week no recovery was observed in the groups. Post-injection, there was a strong and significant improvement in rats receiving rESC and ABMDN as compared to the control group based on the BBB scale, and the Train-of-four-Watch SX acceleromyography device exhibited statistically significant (P < 0.0001) regeneration of neural tissue after SCI. Histological evaluation of the spinal cord showed maximum vacuolization and least gliosis in the control group compared to the rESC and ABMDN treated animals. In the ABMDN group, limited vacuolization and more prominent gliosis were observed in all specimens as compared to the control and rESC groups.

This study provided strong evidence to support that transplantation of rESC and ABMDN can improve functional recovery after iatrogenic SCI. The transplanted cells showed a beneficial therapeutic effect when compared to the control group.

Spinal cord injury (SCI) is an important cause of traumatic paralysis and is mainly due to motor vehicle accidents. It is reported that in United States over 200000 patients suffer injury to the spinal cord and over 50% of spinal cord injured individuals are considered paraplegic and about 48% quadriplegic. Approximately > 10000 new injuries occur each year of which 82% occur in males and 56% of injuries occur in young people < 30 years[1]. The total direct cost for care of spinal cord injured patients in the United States is approximately $7.736 billion[2]. The yearly incidence of traumatic SCI worldwide is about 15-40 cases per million[3]. Despite serious preventive measures to reduce the injuries causing traumatic paraplegia, the incidence of such injuries is increasing. In addition, although many treatments to reverse total paralysis have been tried, we currently do not have effective therapies to reverse this disabling condition.

Spinal cord bypass surgery using peripheral nerves[4], olfactory ensheathing cells[5,6] Schwann cells for transplantation[7] and neural stem cells (NSC)[8] have been performed. Studies in animals have shown improvements in injured spinal cord function when cells derived from the embryonic central nervous system of mice were transplanted[9]. In another report, adult stem cells from the central nervous system were also used with limited success[10-12]. Recently Syková et al[13] (2006) injected mesenchymal stem cells (MSCs) into the spinal cord in rats with iatrogenic injury and found acceptable functional recovery, which was confirmed histologically. These results were similar to those reported by Kang et al[14]. In a recent review, Han et al[15] (2019) reported the extraction of MSCs from various sources, which included bone marrow, adipose tissue, synovium, umbilical cord and human blood. In animal models, MSCs-based therapies had a beneficial effect on locomotor recovery[16,17], but the results could not be replicated or in vitro.

Expanded MSCs have a short life span and they disappear within 24 h[18], while terminal cells such as neurocytes remain alive for about 90 d.

Our objective was to study the outcome of rat embryonic stem cells (rESC) and autologous bone marrow-derived neurocytes (ABMDN) in iatrogenic SCI created in rats, and to compare the efficacy of the two different cell types.

This study was carried out following approval by the Institutional Review Board of the University of Dammam, which was in accordance with the ethical guidelines of the 1975 Declaration of Helsinki.

Surgical steps

A drop weight device was standardized, which consisted of a 10 g weight dropped from a height of 25 cm. The study included 45 male Wistar rats weighing between 250 and 300 g (Figure 1). The animals were kept in the similar cages and had similar feeding habits. They were divided into the following three groups: Group I was the control group, Group II was the rESC group and Group III was the ABMDN group. rESC were obtained from Celprogen Inc., Torrance, CA, United States and ABMDN were harvested at the university’s stem cell laboratory. The animals were anesthetized with ketamine 50 mg/kg body weight and xylazine 35 mg/kg). Sterile eye drops were instilled to keep the eyes moist during surgery. The fur was clipped and the surgical area was cleaned with betadine. An incision was made over the lower thoracic area (Figure 2), muscle and connective tissues were bluntly dissected to expose the thoracic 8^th to lumbar 1^st vertebrae. A T10-thoracic 12^th vertebrae laminectomy was performed, avoiding any injury to the spinal cord. A 10 g weight was dropped from a height of 25 cm onto the exposed spinal cord (Figure 3A and B). The wound was closed in layers. Diclofenac 1 mg/kg body weight as an analgesic and floxacillin 3 mg/kg body weight were given. Postoperatively, Ringer lactate 5 mL/100 g was given subcutaneously. Following surgery, the rats were monitored thrice a day for one week. The urinary bladder was manually evacuated twice daily and Ringer lactate 5 mL/100 g was administered for the first week after surgery.

Open in New Tab   Full Size Figure   Download Figure

Figure 1 Surgical marking to identify lower thoracic and upper lumbar spine.

Open in New Tab   Full Size Figure   Download Figure

Figure 2 Surgical images. A and B: Surgical image of the spinal cord; C and D: The spinal cord before removal.

Open in New Tab   Full Size Figure   Download Figure

Figure 3 Control group showing extensive vacuolization. A: H&E × 200; B: H&E × 400. Highlighted by a single arrow.

On the 10^th day after creation of the SCI all the rats underwent nerve conduction studies and behavioral assessment (Basso, Beattie, Bresnahan [BBB])[19] to confirm paraplegia. The BBB scale, which was described in 1995, is a 21-point scale which assesses trunk stability, hind limb movements, stepping with coordination and clearance of toes, and tail position. Following the drop weight SCI, injection of rESC, ABMDN or saline was administered on the 10^th day. Behavioral assessment using the BBB scale was conducted prior to cell transplantation. Once paraplegia was confirmed the injured site was reopened and in the controls 1 mL of normal saline (Group I), 4 million rESC (Group II) and 4 million ABMDN (Group III) was injected. The wound was closed in layers. At the end of the 8-wk period nerve conduction tests were performed using Train-of-four (TOF)-Watch SX, which is the current "clinical gold standard", for measuring recovery of nerve blockade. In TOF nerve stimulation, the ratio of the fourth muscle contraction (twitch) to the first twitch is recorded; when this ratio is 90% (or 0.9) or greater, full recovery of muscle strength is present indicating nerve recovery.

The animals were euthanized after 8 wk and spinal cords were isolated (Figure 4A and B) and placed in 2% formalin for histopathological analysis to assess healing of neural tissues at the axonal level.

Open in New Tab   Full Size Figure   Download Figure

Figure 4 Control group showing minimum gliosis. A: H&E × 200; B: H&E × 400. Highlighted by a single arrow.

All the animals tolerated the procedure well. Eight weeks after implantation, the assessment of locomotion by BBB and electromyographic studies was carried out and animals were then euthanized and spinal cord was dissected out and sent for histopathological studies.

Histological studies

Cross-section of the spinal cord showed dissolved and degenerated cells with the formation of varying extents of vacuolization and reactive gliosis in the control group (Figures 3 and 4), whereas the spinal cords in rESC transplanted animals were smaller and further apart with more reactive gliosis and no tumor formation (Figures 5 and 6). In the ABMDN group, limited vacuolization and more prominent gliosis were observed in all specimens compared to the controls (Figures 7 and 8). Overall, the specimens exposed to ABMDN demonstrated less pronounced vacuolization and enhanced reactive gliosis as compared to specimens exposed to rESC. This was further confirmed by glial fibrillary acidic protein staining (Figure 9).

Open in New Tab   Full Size Figure   Download Figure

Figure 5 Spinal cord injury treated with rat embryonic stem cells showing vacuolization at the peripheral area of a longitudinal section of the spinal cord. A: H&E × 200; B: H&E × 400.

Open in New Tab   Full Size Figure   Download Figure

Figure 6 Section (× 400 HPF) shows reactive gliosis in rat embryonic stem cells-treated spinal cord injury.

Open in New Tab   Full Size Figure   Download Figure

Figure 7 Spinal cord injury treated with autologous bone marrow-derived neurocytes showing limited vacuolization. A: H&E × 200; B: H&E × 400.

Open in New Tab   Full Size Figure   Download Figure

Figure 8 Autologous bone marrow-derived neurocytes-treated spinal cord injury showing prominent gliosis. A: H&E × 200; B: H&E × 400.

Open in New Tab   Full Size Figure   Download Figure

Figure 9 Comparison of glial fibrillary acidic protein staining. A: Rat embryonic stem cells; B: Autologous bone marrow-derived neurocytes.

Our study found that iatrogenic SCI can functionally and neurologically recover after rESC and ABMDN transplantation compared with the control group. When the outcome in the rESC and ABMDN groups was compared, the latter showed better results on the BBB scale, electromyographic and histological analysis. Ye et al[20] (2018) conducted a trial using bone mesenchymal stem cells (BMSCs) and BMSC neural-like cells and showed that human cerebrospinal fluid-derived neural-like cells fared better when the cells were transplanted into the lateral ventricles. Our results also confirmed that ABMDN resulted in a better outcome than rESC. Muniswami et al[21] (2018) used bone marrow-derived MSCs and found that these cells improved healing of the injured spinal cord.

The question arises whether to use MSCs or rESC or the terminal neurocytes. When MSCs enter the circulation, they need to be transformed to terminal cells for reasonable function. During the course of transformation to neurocytes, transformation can be arrested at any time. Secondly, rESC when given intravenously can differentiate into any cell type with a short life span and carry the risk of teratoma formation[22]. The life span of neurocytes has been reported to be between 90-120 d with no risk of tumor formation as these are autologous derived cells.

Jung et al[23] (2009) compared allogenous, autogenous, and control stem cells, and reported that in the control group the recovery was minimal compared to either the allogenous or autogenous stem cell group. This indicates that allogenous stem cells do work but the immune reactions need to be overcome.

Different routes of administration for cell therapies in SCI have been tried. Amemori et al[24] (2015) injected NSCs either intraspinally or directly into the subarachnoid space of rats and found that both methods resulted in recovery. The report by Cheng et al[25] (2012) further supported this method of injection with acceptable recovery.

In the present study, we transplanted the cells directly at the injury site with improved results. Our results are similar to those reported by other researchers in the field. Intravenous administration of hNSCs has been reported to have good therapeutic potential, is less invasive, and avoids a second surgery. This type of therapy needs to be investigated further[26,27]. The literature on stem cell therapy has shown that it is quite promising and can be used in many diseases after appropriate controlled trials. Of these diseases, SCI has shown slow recovery following many modes of treatment. The use of stem cell therapy in SCI in recent years has shown improvement in neural function, which was once believed to be unachievable[28,29].

Recently, trials to heal SCI have used different types of cells for transplantation, including neural stem/progenitor cells (NS/PCs)[16,30], Schwann cells[31], olfactory ensheathing glia[32], MSCs[33] and oligodendrocyte progenitor cells[34] with varying success. The use of scaffolds especially biological scaffolds is emerging as a potential game changer for reducing necrosis, local inflammatory reactions, otherwise could increase necrosis at the site of SCI[35]. Recently, Koffler et al[36] (2019) convincing showed that 3D biomimetic scaffolds with the use of neural progenitor cells enhanced growth and regeneration in host cells. For the first time we used ABMDN in rats and these cells provided better results than rESCs even without a scaffold. It is probable that recovery using a scaffold could lead to further improvement.

In conclusion, the present study provides strong evidence, based on the BBB scale, electromyographic and histopathological studies, to support that transplantation of ABMDN could improve functional recovery after iatrogenic SCI. The transplanted ABMDNs showed a beneficial therapeutic effect. As recovery was ≥ 60% in 8 wk, this is sufficient to warrant large-scale, randomized controlled studies to evaluate their efficacy in larger animals and in humans.